XML 31 R76.htm IDEA: XBRL DOCUMENT v2.4.0.6
Quarterly Financial Information (Unaudited) (Details) (USD $)
 3 Months Ended 12 Months Ended
Dec. 31, 2012
Sep. 30, 2012
Jun. 30, 2012
Mar. 31, 2012
Dec. 31, 2011
Sep. 30, 2011
Jun. 30, 2011
Mar. 31, 2011
Dec. 31, 2012
Dec. 31, 2011
Dec. 31, 2010
Quarterly Financial Information Disclosure [Abstract]                      
License fee and milestone revenue $ 120,546 $ 128,745 $ 127,157 $ 131,088 $ 132,936 $ 183,138 $ 131,664 $ 120,118 $ 82,536 $ 156,397 $ 213,916
Revenue under collaborative research and development arrangements 36,233 116,234 0 0         152,467 0 0
Grants and miscellaneous revenue 977,974 609,717 308,925 1,562,033 1,499,732 2,454,423 2,288,099 2,985,147 3,458,649 9,227,401 5,549,583
Total revenues 1,134,753 854,696 436,082 1,693,121 1,632,668 2,637,561 2,419,763 3,105,265 4,118,652 9,795,257 6,144,705
Research and development 4,442,841 4,972,319 4,527,086 4,042,579 4,158,400 6,987,824 4,463,978 4,421,799 17,984,825 20,032,001 13,256,606
General and administrative 2,919,000 2,674,362 2,696,909 2,488,088 3,253,990 2,323,188 3,092,386 3,319,232 10,778,359 11,988,796 12,108,261
Gain on sale of assets 0 (500,000) 0 (651,000) 0 (337,000) 0 (250,000) (1,151,000) (587,000) 0
Total operating expenses 7,361,841 7,146,681 7,223,995 5,879,667 7,412,390 8,974,012 7,556,364 7,491,031 27,612,184 31,433,797 25,364,867
Loss from operations (6,227,088) (6,291,985) (6,787,913) (4,186,546) (5,779,722) (6,336,451) (5,136,601) (4,385,766) (23,493,532) (21,638,540) (19,220,162)
Interest and other income, net 56,520 37,013 41,036 31,544 18,893 5,738 7,799 1,855 166,113 34,285 147,406
Change in fair value of common stock warrants 3,049,649 (1,113,638) 3,594,782 (3,548,173) 1,113,076 346,956 4,898,758 2,331,868 1,982,620 8,690,658 2,403,924
Gain (Loss) from investment in affiliated entity 2,449,615 736,121 (992,373) (561,544) (840,436) 1,427,176 (2,607,227) (370,011) 1,631,819 (2,390,498) (969,914)
Net gain (loss) (671,304) (6,632,489) (4,144,468) (8,264,719) (5,488,189) (4,556,581) (2,837,271) (2,422,054) (19,712,980) (15,304,095) (17,638,746)
Net loss attributable to non-controlling interest 12,553 10,413 11,289 9,770 11,948 14,649 15,112 9,441 44,025 51,150 24,950
Net gain (loss) attributable to Inovio Pharmaceuticals, Inc. $ (658,751) $ (6,622,076) $ (4,133,179) $ (8,254,949) $ (5,476,241) $ (4,541,932) $ (2,822,159) $ (2,412,613) $ (19,668,955) $ (15,252,945) $ (17,613,796)
Net loss attributable to Inovio Pharmaceuticals, Inc. stockholders (In dollars per share) $ 0.00 $ (0.05) $ (0.03) $ (0.06) $ (0.04) $ (0.04) $ (0.02) $ (0.02) $ (0.14) $ (0.12) $ (0.17)
Weighted average number of common shares—basic and diluted (In shares) 140,704,889 135,389,308 134,968,394 134,968,394 129,382,305 127,256,907 127,256,364 120,922,577 136,509,247 126,239,336 103,201,880